In the recent years, SGLT2 inhibitors have been widely used to treat patients with T2D-DN owing to their important benefits in controlling blood glucose levels, reducing cardio-cerebral vascular events and kidney outcomes in patients with diabetes and severe albuminuria (Uehara-Watanabe et al., 2022). Here, SLC5A2 is linked to diabetes mellitus.